Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

• J. De Castro ^[1] ; J. L. González-Larriba ^[2] ; S. Vázquez ^[3] ; B. Massutí ^[4] ; J. M. Sanchez-Torres ^[24] ; M. Dómine ^[5] ; P. Garrido ^[6] ; A. Calles ^[25] ; A. Artal ^[7] ; R. Collado ^[8] ; R. García ^[9] ; M. Sereno ^[10] ; M. Majem ^[11] ; J. A. Macías ^[12] ; O. Juan ^[26] ; J. Gómez-Codina ^[27] ; B. Hernández ^[13] ; M. Lázaro ^[14] ; A. L. Ortega ^[28] ; M. Cobo ^[15] ; J. M. Trigo ^[16] ; E. Carcereny ^[17] ; C. Rolfo ^[29] ; S. Macia ^[18] ; J. Muñoz ^[19] ; P. Diz ^[30] ; M. Méndez ^[20] ; F. Rosillo ^[21] ; L. Paz-Ares ^[22] ; J. V. Cardona ^[31] ; D. Isla ^[23]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  3. [3] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  4. [4] Hospital General Universitario de Alicante

     Hospital General Universitario de Alicante

     Alicante, España

     
  5. [5] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  6. [6] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  7. [7] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  8. [8] Hospital San Pedro de Alcántara

     Hospital San Pedro de Alcántara

     Cáceres, España

     
  9. [9] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  10. [10] Hospital Infanta Sofia

      Hospital Infanta Sofia

      Madrid, España

      
  11. [11] Hospital de la Santa Creu i Sant Pau

      Hospital de la Santa Creu i Sant Pau

      Barcelona, España

      
  12. [12] Hospital Morales Meseguer

      Hospital Morales Meseguer

      Murcia, España

      
  13. [13] Gobierno de Navarra

      Gobierno de Navarra

      Pamplona, España

      
  14. [14] Complexo Hospitalario Universitario de Vigo

      Complexo Hospitalario Universitario de Vigo

      Vigo, España

      
  15. [15] Hospital Regional Universitario de Málaga

      Hospital Regional Universitario de Málaga

      Málaga, España

      
  16. [16] Hospital Universitario Virgen de la Victoria

      Hospital Universitario Virgen de la Victoria

      Málaga, España

      
  17. [17] Institute Catalá Oncología

      Institute Catalá Oncología

      Barcelona, España

      
  18. [18] Hospital General de Elda

      Hospital General de Elda

      Elda, España

      
  19. [19] Hospital Universitario Doctor Peset

      Hospital Universitario Doctor Peset

      Valencia, España

      
  20. [20] Hospital de Móstoles

      Hospital de Móstoles

      Móstoles, España

      
  21. [21] Complejo Hospitalario Torrecárdenas de Almería

      Complejo Hospitalario Torrecárdenas de Almería

      Almería, España

      
  22. [22] Hospital Universitario Virgen del Rocío

      Hospital Universitario Virgen del Rocío

      Sevilla, España

      
  23. [23] Hospital Clínico Universitario Lozano Blesa

      Hospital Clínico Universitario Lozano Blesa

      Zaragoza, España

      
  24. [24] MD Anderson Cancer Center Madrid, España
  25. [25] Centro Integral Oncológico Clara Campal, España
  26. [26] Hospital Arnau Vilanova, España
  27. [27] Hospital La Fe, España
  28. [28] Complejo Hospitalario de Jaén, España
  29. [29] University Hospital of Antwerp, Bélgica
  30. [30] Complejo Asistencial Universitario de León, España
  31. [31] Roche Farma, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 2 (February 2017), 2017, págs. 219-226
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.

    Patients and methods This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.

    Results Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.

    Conclusion Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.